Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Gong-Yan Chen · SciRah

Researcher profile · Semantic Scholar

Gong-Yan Chen

Share profile

Gong-Yan Chen — researcher profile on SciRah

h-index: 44
Works: 222
Citations: 12K

Most-cited papers

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Jie Wang, Cai-Cun Zhou, W. Yao, Qiming Wang +26 more
2022The Lancet Oncology372 citations
Semantic Scholar
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Cai-Cun Zhou, Gong-Yan Chen, Yun-Chao Huang, Jian-Ying Zhou +32 more
2020The Lancet Respiratory Medicine372 citations
Semantic Scholar
Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).
Yun-Peng Yang, Zhe-Hai Wang, Jian Fang, Qi-Tao Yu +30 more
2020Journal of Thoracic Oncology296 citations Open access
Semantic Scholar
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
Shun Lu, Xiao-Rong Dong, H. Jian, Jian-Hua Chen +55 more
2022Journal of Clinical Oncology263 citations Open access
Semantic Scholar
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
Cai-Cun Zhou, Lin Wu, Yun Fan, Zhe-Hai Wang +22 more
2021Journal of Thoracic Oncology252 citations Open access
Semantic Scholar
Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.
S. Ren, Jian-Hua Chen, Xing-Xiang Xu, T. Jiang +29 more
2021Journal of Thoracic Oncology241 citations Open access
Semantic Scholar
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Yuankai Shi, Gong-Yan Chen, Xiang Wang, Yun-Peng Liu +18 more
2022The Lancet Respiratory Medicine201 citations
Semantic Scholar
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xing-Ya Li, Le-Jie Cao +20 more
2021The Lancet Respiratory Medicine182 citations
Semantic Scholar
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
Cai-Cun Zhou, Xing-Ya Li, Qiming Wang, G. Gao +13 more
2020Journal of Clinical Oncology175 citations
Semantic Scholar
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Qing Zhou, Chong-Rui Xu, Ying Cheng, Yun-Peng Liu +16 more
2021Cancer Cell171 citations Open access
Semantic Scholar
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Qing Zhou, Ming Chen, O. Jiang, Yi Pan +30 more
2022The Lancet Oncology170 citations
Semantic Scholar
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
Ying Cheng, Qiming Wang, Kai Li, Jian-Hua Shi +11 more
2021British Journal of Cancer144 citations Open access
Semantic Scholar
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study.
Yun-Peng Yang, Jiya Sun, Zhe-Hai Wang, Jian Fang +27 more
2021Journal of Thoracic Oncology129 citations Open access
Semantic Scholar
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Cai-Cun Zhou, Yina Wang, Jun Zhao, Gong-Yan Chen +22 more
2020Clinical Cancer Research109 citations
Semantic Scholar
Nutritional assessment and risk factors associated to malnutrition in patients with esophageal cancer.
Jing-Jing Cao, Hong-Xia Xu, Wei Li, Zeng-Qing Guo +43 more
2020Current Problems in Cancer109 citations
Semantic Scholar
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study
Yi-Long Wu, Li Zhang, Yun Fan, Jian-Ying Zhou +12 more
2020International Journal of Cancer89 citations Open access
Semantic Scholar
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Li Zhang, Zhe-Hai Wang, Jian Fang, Qi-Tao Yu +11 more
2022Lung Cancer79 citations
Semantic Scholar
Extension protocol for the Investigation on Nutrition Status and Clinical Outcome of Patients with Common Cancers in China (INSCOC) study: 2021 update
Hong-Xia Xu, Chunhua Song, L. Yin, Chang Wang +48 more
202279 citations
Semantic Scholar
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
Ying Cheng, Wei Zhang, Lin Wu, Cai-Cun Zhou +51 more
2024JAMA Oncology75 citations Open access
Semantic Scholar
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.
Shun Lu, Jianying Zhou, H. Jian, Lin Wu +40 more
2023The Lancet Respiratory Medicine70 citations
Semantic Scholar
Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial.
Cai-Cun Zhou, Gong-Yan Chen, Yun-Chao Huang, Jian-Ying Zhou +52 more
2023Journal of Thoracic Oncology69 citations Open access
Semantic Scholar
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
H. Zhong, Sheng-Jie Sun, Jian-Hua Chen, Zi-Ping Wang +40 more
2024The Lancet Respiratory Medicine58 citations
Semantic Scholar
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
Yuan-Kai Shi, Gong-Yan Chen, Xiang Wang, Yun-Peng Liu +18 more
2022Journal of Thoracic Oncology55 citations Open access
Semantic Scholar
Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study
Qing Zhou, Ying Cheng, Yun-Peng Liu, Gong-Yan Chen +11 more
202052 citations Open access
Semantic Scholar
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study
J Zhang, Yue-Yin Pan, Q. Shi, Guojun Zhang +36 more
2021Cancer Communications51 citations Open access
Semantic Scholar
Investigation on nutrition status and clinical outcome of patients with common cancers in Chinese patients: a multicenter prospective study protocol
Hong-Xia Xu, Chunhua Song, Chang Wang, Zhenming Fu +41 more
202051 citations Open access
Semantic Scholar
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
T. Jiang, Jian-Hua Chen, Xing-Xiang Xu, Ying Cheng +31 more
2022Molecular Cancer44 citations Open access
Semantic Scholar
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
X. Ai, Yue-Yin Pan, Jian-Hua Shi, N. Yang +33 more
2021Journal of Thoracic Oncology40 citations Open access
Semantic Scholar
Cancer cachexia statistics in China
Xiang-Rui Li, Chun-Lei Hu, Qi Zhang, Kun-Hua Wang +47 more
202230 citations
Semantic Scholar
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
Shun Lu, Xiao-Rong Dong, H. Jian, Jian-Hua Chen +53 more
2024Cancer Communications29 citations Open access
Semantic Scholar
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study
Cai-Cun Zhou, Gong-Yan Chen, Yun Huang, Jianying Zhou +52 more
2024Journal for ImmunoTherapy of Cancer28 citations Open access
Semantic Scholar
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
Shun Lu, Jian Fang, Xing-Ya Li, Le-Jie Cao +20 more
2022JTO Clinical and Research Reports26 citations Open access
Semantic Scholar
Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
Shun Lu, Xiao-Rong Dong, H. Jian, Jian-Hua Chen +16 more
202126 citations
Semantic Scholar
Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.
Xian Sun, Chia-Wei Li, Wei‐Jan Wang, Mei-Kuang Chen +10 more
2020American Journal of Cancer Research25 citations
Semantic Scholar
Investigation of nutritional status in Chinese patients with common cancer
Chunhua Song, Kun-Hua Wang, Zeng-Qing Guo, Zhen-Ming Fu +46 more
2020Scientia Sinica Vitae24 citations Open access
Semantic Scholar
Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer: a multicenter, single-arm, phase 2b study.
Yuan-Kai Shi, Bao-Lan Li, Lin Wu, Yue-Yin Pan +37 more
2022Journal of Thoracic Oncology23 citations Open access
Semantic Scholar
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy
Feng-Ying Wu, T. Jiang, Gong-Yan Chen, Yun-Chao Huang +35 more
2022Cancer Communications22 citations Open access
Semantic Scholar
Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
Ying Cheng, Qiming Wang, Kai Li, Jian-Hua Shi +7 more
2021Cancer Medicine22 citations Open access
Semantic Scholar
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
S. Ren, Jian-Xing He, Yong Fang, Gong-Yan Chen +8 more
2022JTO Clinical and Research Reports21 citations Open access
Semantic Scholar
Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.
Shun Lu, Yi-Ping Zhang, Guojun Zhang, Jianying Zhou +51 more
2022Journal of Thoracic Oncology21 citations Open access
Semantic Scholar
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
Jian-Hua Chang, Gong-Yan Chen, Dong Wang, Guihua Wang +7 more
2020Cancer Medicine21 citations Open access
Semantic Scholar
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
G. Gao, Jun Zhao, S. Ren, Yina Wang +9 more
2021Annals of Translational Medicine20 citations Open access
Semantic Scholar
Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.
Yuan-Kai Shi, Yan-Qiu Zhao, Sheng Yang, Jian-Ying Zhou +18 more
2022Journal of Thoracic Oncology19 citations Open access
Semantic Scholar
Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.
Shun Lu, Qing Zhou, Xiao-Qing Liu, Ying-Ying Du +22 more
2022Journal of Thoracic Oncology18 citations Open access
Semantic Scholar
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
G. Gao, J. Ni, Yina Wang, S. Ren +18 more
2021Translational Lung Cancer Research17 citations Open access
Semantic Scholar
GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
Qing Zhou, Ming Chen, Gang Wu, Jian-Hua Chang +7 more
2020Translational Lung Cancer Research17 citations Open access
Semantic Scholar
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial.
Bao-Hui Han, Trevor Feinstein, Yuan-Kai Shi, Gong-Yan Chen +25 more
2024The Lancet Respiratory Medicine15 citations
Semantic Scholar
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study
Yong-Feng Yu, Yongxin Ren, Jian Fang, Le-Jie Cao +26 more
2022Therapeutic Advances in Medical Oncology15 citations Open access
Semantic Scholar
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
Jian-Hua Shi, Ying Cheng, Qiming Wang, Kai Li +7 more
2022Frontiers in Medicine15 citations
Semantic Scholar
Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).
Shun Lu, Xiao-Rong Dong, H. Jian, Jian-Hua Chen +16 more
2022Journal of Clinical Oncology13 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Jiu-Wei Cui×23
Invite
Jiu-Wei Cui — researcher profile on SciRah
Jian-Hua Shi×22
Invite
Jian-Hua Shi — researcher profile on SciRah
Jian Fang×21
Invite
Jian Fang — researcher profile on SciRah
Ying Cheng×15
Invite
Ying Cheng — researcher profile on SciRah

×15

Invite

Yue-Yin Pan — researcher profile on SciRah

Invite

Yun Fan — researcher profile on SciRah

Jian-Ying Zhou×14

Invite

Jian-Ying Zhou — researcher profile on SciRah

Zhe-Hai Wang×14

Invite

Zhe-Hai Wang — researcher profile on SciRah

Cai-Cun Zhou×13

Invite

Cai-Cun Zhou — researcher profile on SciRah

Invite

N. Yang — researcher profile on SciRah

Invite

Shun Lu — researcher profile on SciRah

Jian-Hua Chen×12

Invite

Jian-Hua Chen — researcher profile on SciRah